China Proceeds with mRNA RSV Vaccine Candidate – Precision Vaccinations

(Precision Vaccinations News)

The board of directors of CSPC Pharmaceutical Group Limited announced on July 11, 2024,that the mRNA Respiratory Syncytial Virus (RSV) vaccine candidate (SYS6016) has obtained approval from the National Medical Products Administration of the Peoples Republic of China to conduct human clinical trials in China.

Currently, there is no vaccine available in China that protects people fromRSV infection.

In preclinical studies, SYS6016translatedinto the prefusion conformation F-protein in vivo and induced high titers of long-lasting neutralizing antibodies.

CSPC wrote that this vaccine candidateexhibits good protection against RSV-A and RSV-B subtype viral strains and has a good safety profile.

CSPC confirmed it would endeavor to advance the clinical research and market SYS6016 as soon as possible to create value for society and shareholders.

As of July 13, 2024, three RSV vaccines and one monoclonal antibody for infants (Beyfortus) were approved for use in the United States.

Continued here:

China Proceeds with mRNA RSV Vaccine Candidate - Precision Vaccinations

Related Posts
Tags: